PRODUCT CHARACTERISTICS

Each lot of IL-2/TCGF is analyzed for its ability to stimulate proliferation of seven to ten day old PHA-transformed human T-lymphocytes. When used at a final concentration of approximately 10% (v/v), IL-2/TCGF will induce a minimum five-fold increase in cell concentration of such cells when seeded at a density of 2.0 x 10^5/ ml. IL-2/TCGF, a glycoprotein with a molecular weight of approximately 15,000 kDa, is produced from pooled human PHA-stimulated T-lymphocytes. IL-2/TCGF is purified by several chromatographic steps to remove PHA and interferon.

RECOMMENDED USAGE

This preparation will support growth of most IL-2/TCGF dependent lymphocyte cultures at a final concentration of 10% (v/v). The initial cell density should be approximately 2.0 x 10^5/ ml and the cell culture should be adjusted to this density every four to five days by additional feeding with 10% IL-2/TCGF. The initial cell population may need to be blast-transformed by either mitogenic or antigenic stimulation such as with PHA. Optimal concentration of IL-2/TCGF and/or mitogen must be determined experimentally by the investigator.

CONTENTS

Each 50 ml bottle contains approximately 25,000 BRMP (Biological Response Modifier Program) units of IL-2/TCGF at a concentration of approximately 500 BRMP units/ml. It is supplied as a sterile solution in 25mM HEPES buffered RPMI 1640 culture medium which is free of serum. IL-2/TCGF protein concentration ranges from 8-22 µg/ml.

STORAGE AND STABILITY

The solution is stable at -10ºC or below. The material may be re-frozen after thawing. Repetitive freezing and thawing is not recommended (aliquot if necessary). Thawed material may be stored at 4ºC for short-term usage.

CAUTION

Human Source Material (Human Blood) used in the manufacture of this product has been tested and found to be negative for HBsAG, antibodies to HIV-1/HIV-2 and HCV. Handle as if capable of transmitting infectious agents; use Universal Precautions when working with this product.